

23 Sep 2026 · 2m · 3 chapters

Meta’s new AI agent “Muse” is popular with users/investors but facing privacy and authorization backlash; plus brief AI/biotech/defense business updates.
No guests mentioned; it’s a Wall Street Journal “TNB Tech Minute” read by Danny Lewis.
Meta says each Muse agent runs on a secure, dedicated computer, but analysts warn a major hack or agents using users’ logins/credit cards could harm the industry. Amazon blocked Muse from accessing its site and purchasing for users, saying it wasn’t authorized or informed.
Amazon’s block; Invada Biosciences valuation doubling to ~$2B for drug discovery and trials; Sensofusion seeking ~$344M IPO in Helsinki with anti-drone tech deployed in Ukraine and the Middle East.
Written by AI. May contain mistakes.
Discussion on Meta's new AI agent, user reception, and privacy concerns.
“I'm Danny Lewis for The Wall Street Journal.”
Highlighting Invada Biosciences' valuation increase and drug development.
“Elsewhere in AI, the journal exclusively reports that Invada Biosciences, which uses the technology to streamline early-stage drug discovery, has doubled its valuation to about$2 billion.”
Overview of Sensofusion's IPO plans and its defense technology applications.
“Sensofusion, which makes anti-drone software, has a contract with the U.S.”

Get the gist, explore an idea or ask about something said.
On WSJ Tech News Briefing, what are the key points of this episode?
Automatic transcript. May contain errors.
0:00Why can't we get AI to production? Our competitors are already... How do we keep data secure? AWS AI cuts through the noise. With ready-to-use agents and the broadest set of AI tools, stop overthinking. Start building. AWS AI is how. Here's your morning TNB Tech Minute for Wednesday, September 23rd. I'm Danny Lewis for The Wall Street Journal. Meta's new AI agent appears to be a hit with users and investors, but it's already facing scrutiny over privacy concerns. Though Meta says each of its Muse agents run on their own secure, dedicated computer, analysts say a major hack or incidence of agents going rogue with users' logins or credit cards could cast a negative light on the industry.
0:43Meanwhile, Amazon has blocked Muse from accessing its site and purchasing items for its users. The online shopping giant says it wasn't made aware of in advance that Muse would be accessing its store and that it didn't authorize the activity. Meta declined to comment on Amazon's action. Elsewhere in AI, the journal exclusively reports that Invada Biosciences, which uses the technology to streamline early-stage drug discovery, has doubled its valuation to about$2 billion. The financing will help Invada fund later-stage human trials. The company has an experimental daily pill designed to help patients maintain weight loss after discontinuing GLP-1 medications, and is also testing drugs for atopic dermatitis and inflammatory bowel disease.
1:26And a Finnish defense company is seeking$344 million by going public in Helsinki. Sensofusion, which makes anti-drone software, has a contract with the U.S. Marine Corps and has deployed its technology in both Ukraine and the Middle East. The company says three pension insurance companies and a fund management group have committed 170 million euros to anchor the IPO. Proceeds will be used to develop the group's technology and to expand production and testing into different markets. And that's your T &B Tech Minute. We'll be back this afternoon with more. Why can't we get AI to production? Our competitors are all ready.
2:01How do we keep data secure? AWS AI cuts through the noise. With ready-to-use agents and the broadest set of AI tools, stop overthinking, start building. AWS AI is how.
Plus: AI biotech firm Enveda doubles valuation to $2 billion. And Finnish drone maker Sensofusion seeks $344 million in Helsinki IPO. Danny Lewis hosts.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.